Servier Selects Onco360 as Pharmacy Partner for Tibsovo

Approved in May 2022, Tibsovo is the first therapy targeting cancer metabolism for older patients with newly diagnosed IDH1-mutated acute myeloid leukemia.

Servier Pharmaceuticals has chosen Onco360 to be a specialty pharmacy partner for Tibsovo (ivosidenib). Tibsovo is the first therapy targeting cancer metabolism for patients with newly diagnosed IDH1-mutated acute myeloid leukemia.

AML is a difficult-to-treat cancer of the blood and bone marrow and is one of the most common types of leukemia in adults with about 20,000 new cases estimated in the United States each year. The IDH1 gene provides instructions for making the enzyme isocitrate dehydrogenase 1, which produces a molecule necessary for cellular processes. IDH1 mutations are present in about 6% to 10% of AML cases.

Related: FDA Approves Tibsovo Combination for Older Patients with Leukemia

The FDA approved Tibsovo in May 2022 in combination with azacitidine for the treatment of patients with newly diagnosed IDH1-mutated acute myeloid leukemia. It is indicated for adults 75 years or older or those who are ineligible for intensive induction chemotherapy. It is also indicated to treat patients relapsed or refractory AML and locally advanced metastatic bile duct cancer.